• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by IRIDEX Corporation (Amendment)

    6/21/21 5:14:26 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $IRIX alert in real time by email
    SC 13D/A 1 irix_13da.htm SCHEDULE 13D/A Schedule 13D

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No 1.)*

    Iridex Corporation

    (Name of Issuer)

    Common Stock

     

    (Title of Class of Securities)

    462684101 (CUSIP Number)

    Scott A Shuda

    BlueLine Partners

    3480 Buskirk Ave, Suite 215

    Pleasant Hill, CA 94523

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    June 14, 2021

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)


    BlueLine Capital Partners, LP
    20-2141786

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    x
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    WC

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    0

     

    8.

     

    SHARED VOTING POWER
     
    0

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    0

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    493,673

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.2%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     

    .

     

     


     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    BlueLine Capital Partners II, LP
    20-4921646

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    x
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    WC

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    0

     

    8.

     

    SHARED VOTING POWER
     
    264,137

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    264,137

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    493,673

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.2%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     

    .


     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    BlueLine Capital Partners III, LP
    20-5334797

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    x
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    WC

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    0

     

    8.

     

    SHARED VOTING POWER
     
    0

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    0

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    493,673

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.2%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     

    .


     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    BlueLine Partners, LLC
    20-2141854

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    x
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    WC

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    0

     

    8.

     

    SHARED VOTING POWER
     
    264,137

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    264,137

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    493,673

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.2%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     

    .


     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Meridian OHC Partners, LP
    46-3724228

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    x
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    WC

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    0

     

    8.

     

    SHARED VOTING POWER
     
    129,897

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    129,897

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    493,673

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.2%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     

     +


     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    TSV Investment Partners, LLC
    27-1033220

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    x
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    WC

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    0

     

    8.

     

    SHARED VOTING POWER
     
    129,897

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    129,897

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    493,673

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.2%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     


     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Scott Shuda

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    x
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    WC

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    23,306

     

    8.

     

    SHARED VOTING POWER
     

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    23,306

     

    10.

     

    SHARED DISPOSITIVE POWER
     

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    493,673

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.2%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     


     

     

    Item 1.  Security and Issuer.

    This Amendment No,. 1 to Schedule 13D relates to Common Stock (the “Common Stock”) of Iridex Corporation (“Iridex” or the “Company”) with its principal executive offices located at 1212 Terra Bella Avenue, Mountain View, CA  94043.

    Item 2.  Identity and Background.

    No change.

     Item 3.  Source or Amount of Funds or Other Consideration.

    No change.

    Item 4.  Purpose of Transaction.

    BlueLine Partners has been a shareholder of the Company since 2005. The investment strategy of BlueLine Partners and Meridian OHC Partners is that of a friendly “activist” investor. Both firms, and Mr. Shuda as their Managing Director, seek to invest in and assist companies experiencing challenges and/or difficult periods in their business. In 2007, BlueLine Partners made a large direct investment in the Company pursuant to which it became a greater than 25% shareholder and acquired the right to nominate two designees to the Company’s board of directors. In October 2012, Mr. Shuda became the third person nominated by BlueLine to the Company’s board of directors.  At that time, Iridex’ shares traded in the $3.70 range. In early 2017, following the Company’s successful December 2016 direct offering at $14.00 per share, Mr. Shuda resigned from the Company’s board, in part, to facilitate BlueLine’s plan to distribute Company shares held by its funds to certain limited partners in such funds.

    In February 2019, the Reporting Entities filed a new Schedule 13D, following which, on April 29, 2019, Mr. Shuda was reappointed to Iridex’ board of directors. In the time since such appointment, there have been several significant changes at the Company, perhaps the most material of which has been the Strategic Collaboration with Topcon Corporation, announced on March 2, 2021, which, among other things, involved Topcon agreeing to provide $19.5 million in cash to Iridex and to become a major distributor of Iridex retina and glaucoma products in numerous jurisdictions outside the U.S. One result of these recent material developments is Iridex stock trading back up to levels last seen in 2018.

    With the recovery of Iridex stock price, BlueLine Partners, and also Meridian OHC Partners, find themselves under some obligation to provide liquidity to certain of their funds’ limited partners.  Accordingly, over the past several weeks, the Reporting Entities have engaged in the distribution and sale of Iridex shares reflecting the requests of these limited partners. As a result of such distributions and sales, the Shares held by the Reporting Entities now represent approximately 3.2% of the shares of Common Stock outstanding. With BlueLine Partners and its affiliates no longer holding at least 5% of the Company’s outstanding shares, BlueLine Partners will no longer have the right to nominate individuals for appointment to Iridex’ board of directors.

    The Reporting Entities remain deeply committed to constructive engagement at Iridex. Reflecting this, at the most recent meeting of the board of directors of Iridex, held on June 16, 2021, Mr. Shuda put forward his name and was elected by his peers to become the new chairman of the board of directors of the Company.

    Item 5.  Interest in Securities of the Issuer.

    As of the date of this Amendment No. 1 to Schedule 13D, each of the Reporting Entities may be deemed to own 493,673 shares of Common Stock (the “Shares”).  The Shares represent approximately 3.2% of the shares of Common Stock outstanding based on 15,625,800 shares of the Company’s Common Stock outstanding at May 6, 2021 as reported in the Company’s Form 10-Q for the Company’s fiscal quarter ended April 3, 2021 as filed with the Securities and Exchange Commission on May 12, 2021.  

    The Reporting Entities are making this single, joint filing because they may be deemed to constitute a “group” within the meaning of Section 13(d)(3) of the Act.  Each Reporting Entity expressly disclaims beneficial ownership of any of the shares of Common Stock other than those reported herein as being owned by it.


    The transactions involving sales of Shares by the Reporting Entities over the past sixty days is provided below. An additional 52,514 Shares in the case of Meridian OHC Partners LP and 6,883 Shares in the case of BlueLine Capital Partners II, LP, were distributed without any consideration to certain limited partners. The price reported in the table below for the transactions is a weighted average daily price for Shares purchased in multiple transactions. The Reporting Entities undertake to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.  The Reporting Entities were previously advised not to make Form 4 filings relating to sales such as these, for which the Reporting Entities have no beneficial interest.

    Date

    Reporting Entity

    Number of Shares

    Price Per share

    5/14/21

    BlueLine Capital Partners, LP

    12550

    $7.64

    5/19/21

    BlueLine Capital Partners, LP

    4593

    $7.78

    5/20/21

    BlueLine Capital Partners, LP

    11019

    $7.74

    5/20/21

    BlueLine Capital Partners II, LP

    5500

    $7.91

    5/21/21

    BlueLine Capital Partners II, LP

    1500

    $7.81

    5/21/21

    BlueLine Capital Partners, LP

    5000

    $7.90

    6/1/21

    BlueLine Capital Partners, LP

    1500

    $7.96

    6/2/21

    BlueLine Capital Partners, LP

    5000

    $7.94

    6/8/21

    BlueLine Capital Partners, LP

    3000

    $7.70

    6/9/21

    BlueLine Capital Partners, LP

    18213

    $7.85

    6/10/21

    BlueLine Capital Partners, LP

    6200

    $7.76

    6/11/21

    BlueLine Capital Partners, LP

    9142

    $7.72

    6/14/21

    BlueLine Capital Partners, LP

    7582

    $7.79

    6/15/21

    BlueLine Capital Partners, LP

    2076

    $7.61

     

    Only the Reporting Entities have the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares that are the subject of this Amendment No. 1 to Schedule 13D.

    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    No change.

    Item 7.  Material to Be Filed as Exhibits.

    The joint filing agreement entered into among the Reporting Entities was filed as Exhibit A to the Schedule 13D filed on February 18, 2019.


     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:  June 21, 2021

     

    SIGNATURES

     

    BlueLine Capital Partners, L.P.

     

    By:  BlueLine Partners, L.L.C.

    Its:  General Partner

     

    By:      /s/ Scott Shuda                                             

    Name:  Scott Shuda

    Title:    Managing Director

     

    BlueLine Capital Partners II, L.P.

     

    By:  BlueLine Partners, L.L.C.

    Its:  General Partner

     

    By:      /s/ Scott Shuda                                             

    Name:  Scott Shuda

    Title:    Managing Director

     

    BlueLine Capital Partners III, L.P.

     

    By:  BlueLine Partners, L.L.C.

    Its:  General Partner

     

    By:      /s/ Scott Shuda                                             

    Name:  Scott Shuda

    Title:    Managing Director

     

     

    BlueLine Partners, L.L.C.

     

    By:      /s/ Scott Shuda                                             

    Name:  Scott Shuda

    Title:    Managing Director

    Meridian OHC Partners, L.P.

     

    By:  TSV Investment Partners, L.L.C.

    Its:  General Partner

     

    By:      /s/ Scott Shuda                                             

    Name:  Scott Shuda

    Title:    Managing Director

     

     

    TSV Investment Partners, L.L.C.

     

    By:      /s/ Scott Shuda                                             

    Name:  Scott Shuda

    Title:    Managing Director

     

     

    By:      /s/ Scott Shuda                                             

    Name:  Scott Shuda

    Get the next $IRIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Iridex Reports First Quarter 2025 Financial Results

      MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarterSold 24 Cyclo G

      5/13/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Report First Quarter 2025 Financial Results on May 13, 2025

      MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 698002. A live and re

      4/30/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025

      MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results Total revenue is expected to be between $11.8 million and $12.0 million, compared to $11.8 million in the comparable quarter of 2024Sold approximately 13,900 Cyclo G6 probes, compared to 13,300 in the prior year quarterSold approximately 24 Cyclo G6 Laser Systems, compared to 22 in the

      4/14/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Dizon Romeo R bought $1,451 worth of shares (1,305 units at $1.11), increasing direct ownership by 13% to 11,205 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/13/25 5:35:24 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $116 worth of shares (100 units at $1.16), increasing direct ownership by 1% to 9,900 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/12/25 5:53:31 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $115 worth of shares (100 units at $1.15), increasing direct ownership by 1% to 9,800 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/9/25 4:46:56 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Financials

    Live finance-specific insights

    See more
    • Iridex Reports First Quarter 2025 Financial Results

      MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarterSold 24 Cyclo G

      5/13/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Report First Quarter 2025 Financial Results on May 13, 2025

      MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 698002. A live and re

      4/30/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Host Strategic Vision Call on April 16, 2025

      MOUNTAIN VIEW, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will host a special call on April 16, 2025 to introduce Iridex and Novel's strategic vision for the Company following Novel's recent strategic investment in Iridex. The Company's management team will host a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 888-596-4144 and providing conference ID: 9584140. A live an

      4/9/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    SEC Filings

    See more
    • SEC Form 10-Q filed by IRIDEX Corporation

      10-Q - IRIDEX CORP (0001006045) (Filer)

      5/13/25 4:43:02 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IRIDEX CORP (0001006045) (Filer)

      5/13/25 4:16:38 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEFA14A filed by IRIDEX Corporation

      DEFA14A - IRIDEX CORP (0001006045) (Filer)

      4/28/25 4:13:02 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Iridex Appoints Patrick Mercer as Chief Executive Officer

      MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. M

      10/3/24 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

      MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. David I. Bruce, President and CEO of Iridex, shared: "The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward mu

      1/24/24 8:00:00 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces the Appointment of Beverly Huss to its Board of Directors

      MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effective, March 17, 2022. In connection with Ms. Huss' appointment to the board, the size of the board was increased from five to six members as of the Effective Date. "I am very pleased to welcome Beverly to our board of directors," said Scott Shuda, chairman of the board of Iridex. "Beverly's extensive management and board experience in the medical device industry and proven track record with non-invasive a

      3/21/22 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $11.00 from $9.00 previously

      5/12/21 11:32:01 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on IRIDEX with a new price target

      Roth Capital reiterated coverage of IRIDEX with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/9/21 8:09:06 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/3/21 12:29:03 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Dizon Romeo R bought $1,451 worth of shares (1,305 units at $1.11), increasing direct ownership by 13% to 11,205 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/13/25 5:35:24 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $116 worth of shares (100 units at $1.16), increasing direct ownership by 1% to 9,900 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/12/25 5:53:31 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $115 worth of shares (100 units at $1.15), increasing direct ownership by 1% to 9,800 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/9/25 4:46:56 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by IRIDEX Corporation

      SC 13D - IRIDEX CORP (0001006045) (Subject)

      11/23/22 4:57:01 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by IRIDEX Corporation

      SC 13D - IRIDEX CORP (0001006045) (Subject)

      9/20/22 2:06:59 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IRIDEX Corporation (Amendment)

      SC 13G/A - IRIDEX CORP (0001006045) (Subject)

      2/10/22 8:17:17 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care